Buscar

Estamos realizando la búsqueda. Por favor, espere...

 Detalle_Publicacion

Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study

Abstract: Background: The relationship between non-steroidal anti-inflammatory drug (NSAID) consumption and breast cancer has been repeatedly studied, although the results remain controversial. Most case-control studies reported that NSAID consumption protected against breast cancer, while most cohort studies did not find this effect. Most studies have dealt with NSAIDs as a whole group or with specific drugs, such aspirin, ibuprofen, or others, but not with NSAID subgroups according to the Anatomical Therapeutic Chemical Classification System; moreover, scarce attention has been paid to their effect on different tumor categories (i.e.: ductal/non-ductal, stage at diagnosis or presence of hormonal receptors). Methods: In this case-control study, we report the NSAID – breast cancer relationship in 1736 breast cancer cases and 1895 healthy controls; results are reported stratifying by the women’s characteristics (i.e.: menopausal status or body mass index category) and by tumor characteristics. Results: In our study, NSAID use was associated with a 24 % reduction in breast cancer risk (Odds ratio [OR] = 0.76; 95 % Confidence Interval [CI]: 0.64–0.89), and similar results were found for acetic acid derivatives, propionic acid derivatives and COXIBs, but not for aspirin. Similar results were found in postmenopausal and premenopausal women. NSAID consumption also protected against hormone + or HER2+ cancers, but not against triple negative breast cancers. The COX-2 selectivity showed an inverse association with breast cancer (i.e. OR < 1), except in advanced clinical stage and triple negative cancers. Conclusion: Most NSAIDs, but not aspirin, showed an inverse association against breast cancer; this effect seems to be restricted to hormone + or HER2+ cancers. Keywords: Breast cancer, Non-steroidal anti-inflammatory drug, Hormone receptor positive breast cancer, HER2 positive breast cancer, Triple negative breast cancer

 Fuente: BMC Cancer. 2016 Aug 20;16(1):660

Editorial: BioMed Central

 Año de publicación: 2016

Nº de páginas: 11

Tipo de publicación: Artículo de Revista

 DOI: 10.1186/s12885-016-2692-4

ISSN: 1471-2407

Autores/as

DE PEDRO M

PÉREZ GÓMEZ, B.

SERVITJA, S.

MORENO, V.

AMIANO, P.

FERNÁNDEZ VILLA, T.

BARRICARTE, A.

TARDON, A.

DÍAZ SANTOS, M.

PEIRO PÉREZ, R.

MARCOS GRAJERA, R.

LOPE, V.

GRACIA LAVEDAN, E.

ALONSO, MH.

MICHELENA ECHEVESTE, MJ.

GARCÍA PALOMO, A.

GUEVARA, M.

CASTAÑO VINYALS, G.

ARAGONÉS, N.

KOGEVINA, M.